ArticleOncotarget2016
Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Development of Glypican 3-Targeting Antibody-Drug Conjugates for Hepatocellular Carcinoma Therapy.Cancer research communications · 2026Article
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives.OncoTargets and therapy · 2023Review
- Advances in CAR-T cell therapy for malignant solid tumors.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.Bioengineered · 2022Article
- Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice.Molecular cancer therapeutics · 2022Article
- Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.Antibody therapeutics · 2022Review
- HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.Cell death & disease · 2021Article
- Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells.Oncology letters · 2021Article
- Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma.Journal of Cancer · 2020Review
- Cross-disease analysis identified novel common genes for both lung adenocarcinoma and lung squamous cell carcinoma.Oncology letters · 2019Article
- Glypicans as Cancer Therapeutic Targets.Trends in cancer · 2018Review
- EphB4: A promising target for upper aerodigestive malignancies.Biochimica et biophysica acta. Reviews on cancer · 2018Review
- Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.Translational oncology · 2018Article
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Review
- Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.Oncotarget · 2017Article
- Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Cancer letters · 2017Review
- Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.Human gene therapy · 2017Article
- Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2017Article
- New Chimeric Antigen Receptor Design for Solid Tumors.Frontiers in immunology · 2017Review
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.Current trends in immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are unmet medical needs for patients with lung squamous cell carcinoma (LSCC). Therefore, in this study, we explored the antitumor potential of third-generation glypican 3 (GPC3)-redirected chimeric antigen receptor (CAR)-engineered T lymphocytes (CARgpc3 T cells) in tumor models of LSCC. First, we demonstrated by immunohistochemistry (IHC) that GPC3 was expressed in 66.3% of LSCC samples and in 3.3% of lung adenocarcinoma (LAD) samples but not in normal lung tissues. In the presence of GPC3-positive LSCC cells, CARgpc3 T cells were highly activated and increased in number. CARgpc3 T cells could specifically lyse GPC3-positive LSCC cells in vitro. In two established LSCC xenograft models, CARgpc3 T cells could almost completely eliminate the growth of GPC3-positive cells. Additionally, the CARgpc3 T cells were able to persist in vivo and efficiently infiltrate the cancerous tissues. Taken together, these findings indicate that CARgpc3 T cells might be a novel potential therapeutic agent for the treatment of patients with LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.